Program at a Glance

| | | _ | | | | |
|-------------|--|---|--|---|-------------|--|
| | | DAY 1 (Sep | tember 15, Thu) | | | |
| | | | | : Korean | : English | |
| Floor | 3F | | | 5F | 6F | |
| Room | 1 | 2 | 3 | 4 | Poster Hall | |
| 11:00 ~ | Registration (5F) | | | | | |
| 12:00~12:50 | Luncheon Symposium 1 [Daewoong] | Luncheon Symposium 2 [Chong Kun Dang] | | | | |
| 12:50~14:20 | Symposium 1 | Basic Research Workshop 1 | Symposium 2 | Symposium 3 | | |
| | Optimal risk factor control in patients with DM | Lipid metabolism & metabolic disorders | Novel risk factors & intervention targets in atherosclerosis | NAFLD, metabolic dysfunction & ASCVD | | |
| 14:20~14:30 | Coffee Break | | | | | |
| 14:30~15:30 | | Oral Presentation 1 (APSAVD Young Investigator Session) | | | | |
| | Symposium 4 | Basic Research Workshop 2 | | Symposium 5 | | |
| 15:30~17:00 | Update on coronary CT: risk marker, monitoring tool & future perspective | SMC plasticity in plaque stability | | Lipid as risk & target in cerebrovascular disease | | |

| | | DAY 2 (Sep | otember 16, Fri) | | | | |
|-------------|---|--|--|--|---|--|--|
| | | <u> </u> | · / | : Korean | : English | | |
| Floor | | 3F | | 5F | 6F | | |
| Room | 1 | 2 | 3 | 4 | Poster Hall | | |
| 07:30 ~ | | | Registration (5F) | | | | |
| 08:00~09:00 | Breakfast Symposium 1 [Celltrionpharm] | Breakfast Symposium 2 [Organon] | | | | | |
| 09:00~09:40 | Plenary Lecture 1 | | | | | | |
| | Target discovery & drug development for atherosclerosis in 2020's | | | | | | |
| 09:40~09:45 | Break | | | | | | |
| | Symposium 6 | Symposium 7 | Symposium 8 | Symposium 9 | | | |
| 09:45~11:15 | Adipose tissue & atherosclerosis | New regulators of dyslipidemia & atherosclerosis | High CV risk group: is it properly defined? | Update on non-pharmacological control of ASCVD risk | | | |
| 11:15~11:25 | | Coffee Break | | | | | |
| 11:25~11:30 | | Opening Address | | | | | |
| 11:30~12:00 | | ry Lecture 2 (APSAVD:Ding Le | • | | B | | |
| | recont developments in the t | disorders | | Poster Viewing | | | |
| 12:00~12:50 | Luncheon Symposium 3 [Organon] | Luncheon Symposium 4 [JW Pharmaceutical] | Luncheon Symposium 5 [Viatris] | Luncheon Symposium 6 [Boehringer Ingelheim/Lilly] | | | |
| 12:50~12:55 | | Break | | | | | |
| | Plenary Lecture 3 | | | | | | |
| 12:55~13:35 | Senescen | ce & vascular smooth muscle ce | | | | | |
| 13:35~15:05 | Symposium 10 Debate on developing risk grouping in Korea: current status, comparison with foreign, & solution | Food & Nutrition Workshop Cardiometabolic disease & customized nutrition management | Symposium 11 Inflammation in progression & inhibition of atherosclerosis | Symposium 12 (IAS/APSAVD/JAS Joint Symposium) Dyslipidaemia | | | |
| 15:05~15:15 | Coffee Break | | | | | | |
| 15:15~16:15 | Oral Presentation 2 | Oral Presentation 3 | 2022 KSoLA Awards for Scientific Excellence & Young Investigator Scientific Excellence Award Lecture | | Moderated Poster 1,2, 5 (Kor / Eng) | | |
| 16:15~17:45 | Symposium 13 | Publication Committee Session | Symposium 14 (JAS/KSoLA Joint Symposium) | Symposium 15 (APSAVD Joint Symposium) | Poster Viewing | | |
| | Debate on new Korean guidelines on dyslipidemia: treatment | Jession | Impact of aging of vascular cells on atherosclerosis & its protection | COVID-19 & cardiovascular risk | | | |

| | | DAY 3 (Sep | tember 17, Sat) | | | |
|-------------|--|---|--|---|--|--|
| | | | | : Korean | : English | |
| Floor | | 3F | | | 6F | |
| Room | 1 | 2 | 3 | 4 | Poster Hall | |
| 07:30 ~ | Registration (5F) | | | | | |
| 08:00~09:00 | Breakfast Symposium 3 [Yuhan] | Breakfast Symposium 4 [JW Pharmaceutical] | | | | |
| 09:00~09:40 | Plenary Lecture 4 | | | | 1 | |
| | New look at PCSK9 metabolism & its clinical implication | | | | | |
| 09:40~09:45 | Break | | | | | |
| | Symposium 16 | Symposium 17 | Symposium 18 | Symposium 19 | | |
| 09:45~11:15 | Current issues in severe dyslipidemia | Emerging targets & drug platforms in dyslipidemia & atherosclerosis | Role & unsolved issues of novel lipid-modifying agents | Current nutritional knowledge in cardiometabolic health | | |
| 11:15~11:25 | Coffee Break | | | | | |
| 11:25~12:05 | Plenary Lecture 5 | | | | | |
| | Best approach to cardio & cerebrovascular health in the elderly | | | | | |
| 12:05~12:55 | Luncheon Symposium 7 [Inno.N] | Luncheon Symposium 8 [Hanmi] | Luncheon Symposium 9 [Amgen] | Luncheon Symposium 10 [Sanofi] | | |
| 12:55~13:00 | Break | | | | | |
| 13:00~13:30 | Plenary Lecture 6 (APSAVD:Yamamoto Lecture) | | | | | |
| 13.00~13.30 | Up close & personal with vascular diseases: the role of precision medicine | | | | | |
| 13:30~13:35 | Break | | | | | |
| 13:35~14:35 | Oral Presentation 4 | Oral Presentation 5 | | | Moderated Poster 3,4 (Kor / Eng) | |
| 14:35~14:45 | Coffee Break | | | | | |
| 14:45~16:15 | Symposium 20 | Symposium 21 | Symposium 22 (TSLA/KSoLA Joint Symposium) | Symposium 23 (APSAVD Joint Symposium) | Poster Viewing | |
| | How will new technologies change our research & patient care in ASCVD? | New concepts in vascular biology | Sex difference in dyslipidemia & atherosclerosis | Update on antibodies & siRNA against PCSK9 | | |
| 16:15~ | | | Closing Ceremony | | | |